Publications

Buch et al. evaluated the efficacy and safety of filgotinib in patients with moderately active rheumatoid arthritis and inadequate response to methotrexate in the FINCH 1 study. At     Wk 12, ACR20 response rates were significantly higher with filgotinib 200 mg (77.9%) and 100 mg (67.8%) compared to placebo (43.8%). Safety profiles for both filgotinib doses were similar to adalimumab.

The study focused on a post hoc subgroup analysis of FINCH 1 trial participants with moderate baseline DAS28-CRP ≤3.2–5.1 and insufficient methotrexate response, aiming to assess clinically meaningful outcomes, including ACR20 and remission, while confirming a stable safety profile.